Table 1 Breast cancer patient demographics and sampling points.

Center	Patient	Diagnosis^a	Age	Hormone receptor status^b			PIK3CA mutation status^c	No. burns (N)^d		No. burns (T)^d
Center	Patient	Diagnosis^a	Age	ER	PR	Her2	PIK3CA mutation status^c	CT	CG	CT	CG
C1	1	ILC	54	+	+	n/d^e	n/d	5	4	4	2
	2	IDC	40	+	+	+	E542R/E545X/Q546X	3	2	0	0
	3	IDC	76	+	+	−	E545X/Q546X	5	5	0	0
	4	IDC	47	+	+	+	n/d	0	0	0	3
	5	IDC	81	+	+	−	n/d	4	5	0	4
	6	DCIS	68	n/d^d	n/d	n/d	H1047R	4	3	0	0
C3	1	IDC	43	+	+	−	WT	5	1	5	3
	2	IDC	73	+	+	−	E545X/Q546X/H1047R	5	2	2	0
	3	ILC	54	+	−	−	WT	5	4	1	0
	4	ILC	86	+	+	n/d	WT	5	3	3	4
	5	IDC	71	+	+	−	WT	5	3	5	5
	6	ILC	49	+	+	−	E545X/Q546X	0	2	3	0
	7	IDC	62	+	+	+	E545X/Q546X/H1047R	0	0	3	3
	8	IDC	80	−	−	−	E542R/H1047R	5	4	2	5
C4	1	IDC	84	−	−	n/d	E542R/C420R/H1047R	8	6	2	2
	2	IDC	70	+	+	−	WT	8	4	0	0
	3	IDC	56	+	+	−	WT	9	5	0	0
	4	IDC	69	+	+	−	n/d	3	2	3	0
	5	IDC	57	−	−	−	E545X/Q546X	0	0	3	1
	6	IDC	88	−	−	+	H1047R	0	0	3	0
	7	IDC	79	+	+	−	WT	3	2	0	0
Total	21	n/a^f						82	57	39	32

^aILC invasive lobular carcinoma, IDC invasive ductal carcinoma, DCIS ductal carcinoma in situ.
^bER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor receptor 2.
^cPIK3CA mutational status associated with tumor tissue sampled. WT wildtype.
^dNumber of sampling events in either normal (N) or tumor (T) tissue, using cut (C) or coagulation (CG) mode.
^eNot determined.
^fNot applicable.

Quick links

Search